Drug Database
DI

diphtheria+tetanus+pertussis combined vaccine

✓ Approved

China National Pharmaceutical · Cell-based Therapies · Cell-based Therapies

What is diphtheria+tetanus+pertussis combined vaccine?

diphtheria+tetanus+pertussis combined vaccine is a cell-based therapies developed by China National Pharmaceutical. It is approved for therapeutic indications via injectable (others) or intramuscular (im) injection.

Drug Profile

CompanyChina National Pharmaceutical
Drug ClassCell-based Therapies, Vaccine
RouteInjectable (Others), Intramuscular (IM) Injection
StatusApproved
Sources: ClinicalTrials.gov, China National Pharmaceutical

Therapeutic Indications

diphtheria+tetanus+pertussis combined vaccine is developed for 3 unique indications across 1 therapeutic area.

Therapeutic AreaConditionPhase
Infections and infestationsDiphtheria✓ Approved
Infections and infestationsPertussis✓ Approved
Infections and infestationsTetanus✓ Approved

Related Research Articles

PubMedFrontiers in medicine2026-09-04

Safe prolonged prophylactic use and tolerability of Ashwagandha following COVISHIELD™ vaccination over 24 weeks: a multicentre randomized double-blind placebo-controlled trial.

Chopra Arvind A, Chaudhuri Susmita S, Gundeti Manohar S MS, Sarmukaddam S S et al.

Ashwagandha (Withania somnifera Dunal) is an Ayurveda medicine that was widely used during the COVID-19 pandemic. In the context of widespread use of herbal formulations alongside COVID-19 vaccination, this study evaluated the safety, tolerability, and exploratory immunological outcomes of Ashwagandha administered following COVISHIELD™ vaccination. 1,200 consenting apparently healthy participants (age 18-70 years) with a negative SARS-CoV-2 RNA assay (RT-PCR using oral and nasal swab) were randomized within 7 days of vaccine administration (primary or booster) to receive oral standardized Ashwagandha (500 mg aqueous root extract) or a matching placebo daily. Participants were monitored every 4 weeks till weeks 28 (study completion) which included comprehensive clinical and laboratory assessment, specific viral RNA and IgG antibody assays (including Wuhan and Delta strain neutralization). Statistical analyses were performed using standard methods, with a two-sided p-value of < 0.05 considered statistically significant. Of the 1,200 randomized participants, 122 (10.2%) were assigned to the SDG (Single Dose Group), 503 (41.9%) to the DDG (Double Dose Group), and 575 (47.9%) to the BDG (Booster Dose Group); overall, 1,032 participants (86%) completed the trial. The safety and tolerability profile of Ashwagandha was comparable to placebo. Adverse events were predominantly gut related and mild, and none caused withdrawal. Following first Covishield™ injection, a persistently higher IgG antibody assay was observed in the Ashwagandha arm (not statistically significant). The cumulative incidence rate of breakthrough infections was 3.9% (95% confidence interval 3.0-5.2%) and did not differ by study intervention. The immunogenic effect of Ashwagandha could not be demonstrated, likely due to a persistently high post-vaccination immune response. In addition, approximately 70% of participants were seropositive for nucleocapsid antibodies at baseline, indicating prior SARS-CoV-2 infection. Prolonged use and tolerability of Ashwagandha in post-vaccinated healthy participants was shown safe but adjunct immunogenicity could not be discerned. Further research is required. http://www.clinicaltrials.gov/, identifier CTRI/2021/06/034496.

PMID 42694770
Read full article →
PubMedThe Milbank quarterly2026-09-04

Vaccine Policy: The State Role in a Time of Public Health Disruption.

Rosenbaum Sara S

Policy Points Over the past year, the nation's highest-ranking public health officials have pursued a concerted strategy of degrading access to childhood vaccines and undermining public confidence in vaccine safety and efficacy. As primary regulators of medical care, states have the power to maintain strong public health protections. A strong childhood vaccination policy has three components: maintaining a robust routine childhood vaccination schedule; focusing on broad vaccine access; and restoring public confidence in the safety and efficacy of childhood immunization. Beginning in 2025, longstanding opponents of vaccines have held the highest positions of federal public health policy powers. Using these powers, high ranking officials have sought to disrupt vaccine coverage and delivery and sow public mistrust in vaccine safety and efficacy. The results of their efforts have been confusion and declining levels of childhood immunization. As of summer 2026, a federal court has enjoined efforts to degrade the childhood vaccine schedule and the public health expertise of the Advisory Committee on Immunization Practices, whose recommendations lie at the heart of US vaccine policy. As the nation's most important regulators of public health practice, states play a critical role in countering these efforts and protecting vaccine accessibility and acceptance.

PMID 42693907
Read full article →
PubMedHealth science reports2026-09-04

HPV Vaccine Uptake, Hesitancy and Information Sources Among Young Adults: A Cross-Sectional Study of Korea and the US.

Jo Soojung S, Xu Dongjuan D, Song Hwanseok H

Despite the high effectiveness of HPV vaccination, uptake among young adults remains suboptimal. Healthcare policies, vaccine hesitancy, and sources of vaccine information may contribute to differences in vaccination behaviors across countries. To examine cross-national and sex-specific differences in HPV vaccine uptake and hesitancy among undergraduates in the US and Korea, and investigate the role of information sources. This cross-sectional study targeted undergraduate students in the US and Korea aged between 18 and 25. Data was collected from August 29, 2023, to February 20, 2024 using an online survey through social media exclusive to college students (Korea) and a university listserv (US). A total of 224 survey responses were analyzed after removing missing data (n = 43). HPV vaccine hesitancy, uptake, and frequency of information source use were assessed. HPV vaccine uptake was substantially higher in the US than in Korea (74.0% vs. 33.1%), with a significant sex gap observed only in Korea. Although no significant cross-national differences in HPV vaccine hesitancy were observed, sex-specific patterns emerged within each country (OR = 5.3; 95% CI = 1.1-25.3; p = 0.035). In the US, females reported slightly higher hesitancy than males, whereas in Korea, males reported greater hesitancy than females. In multivariable logistic regression, frequent use of social media was associated with higher odds of HPV vaccine hesitancy (OR = 3.3, 95% CI = 1.0-10.4, p = 0.043), while frequent use of professional organizations as an information source was associated with lower odds of hesitancy (OR = 0.4, 95% CI = 0.2-0.9, p = 0.024). Tailored public health strategies that address social media's potential role in shaping HPV vaccine hesitancy, while expanded policy support in Korea could improve uptake and reduce hesitancy.

PMID 42694360
Read full article →
PubMedNature reviews. Rheumatology2026-09-04

Vaccination considerations in autoimmune rheumatic diseases.

Kapetanovic Meliha C MC

Patients with autoimmune rheumatic diseases (ARDs) are at increased risk of numerous vaccine-preventable infections owing to a combination of disease-related immune dysregulation, immunosuppressive therapies - including glucocorticoids - and comorbidities. Age-related immunosenescence further increases this susceptibility in older patients. The SARS-CoV-2 (COVID-19) pandemic and measles outbreaks have underscored the importance of optimizing vaccination strategies and improving adherence to recommendations. Nevertheless, coverage for routinely recommended vaccines, including influenza and pneumococcal vaccines, remains suboptimal in this population. Vaccine hesitancy is an important barrier driven by concerns regarding safety, tolerability, disease flares and the potential induction of new autoimmune phenomena. Advanced therapies - including B cell-depleting agents, chimeric antigen receptor T cell therapy and bispecific T cell engagers - can substantially impair vaccine-induced immune responses, highlighting the importance of optimizing vaccination timing in relation to treatment. Although most studies focus on humoral and cellular immune responses, evidence on the long-term durability of vaccine-induced immunity, the need for booster doses and real-world vaccine effectiveness in patients with ARDs remains limited. Ethical considerations are important. Although vaccination in adults is generally not mandatory, improving vaccine uptake reduces the burden of infections in patients with ARDs, contributes to herd immunity and provides indirect protection for other vulnerable populations.

PMID 42693283
Read full article →
PubMedSystematic reviews2026-09-04

Nursing interventions to enhance self-care in heart failure: a systematic review interpreted through the COM-B model.

Kristinawati Beti B, Sukartini Tintin T, Tanaya Violeta Yuman VY, Arifudin Navian Fauzi NF

Heart failure (HF) is a long-term illness, frequently requiring hospital stay and having a significant morbidity and mortality rate. In order to avoid decompensation, lower readmission rates, and promote quality of life, adequate self-care is vital. This review synthesised nursing interventions intended to improve self-care among adults and older adults with HF and retrospectively interpreted their components using the Capability, Opportunity, Motivation-Behaviour (COM-B) model. A systematic search was conducted on 11 November 2025 across seven electronic databases: PubMed, Scopus, Web of Science, CINAHL, Embase, MEDLINE, and PsycINFO. The review included randomised controlled studies evaluating behavioural, educational, psychological, or nursing interventions aimed at improving self-care among adults and older adults with HF. Risk of bias was assessed using the Joanna Briggs Institute Checklist for Randomised Controlled Trials. Database-specific search strategies and publication-year filters are reported in Additional file 1. Nine studies met the inclusion criteria. The interventions included structured education, motivational interviewing, pre-discharge education, technology-based support, and multimodal programmes. Several studies reported improvements in self-care maintenance, management, or confidence; however, the direction and magnitude of effects varied across interventions and follow-up periods. Although none of the studies explicitly used the COM-B model, their intervention components could be retrospectively mapped to Capability, Opportunity, and Motivation. Nursing interventions may improve selected dimensions of HF self-care, particularly when education is combined with follow-up, motivational support, or practical monitoring resources. However, the evidence was heterogeneous, and the magnitude and consistency of effects remain uncertain. COM-B may provide a useful framework for interpreting intervention components, but the retrospective mapping does not demonstrate that COM-B mechanisms were prospectively tested. The procedure of this study was recently filed in the International Prospective Register of Systematic Reviews (PROSPERO) at the National Institute for Health Research (No: CRD420251237974).

PMID 42693477
Read full article →
PubMedThe Lancet regional health. Western Pacific2026-09-04

Long-term projections of cancer prevalence in Australia to 2050: a population-based statistical modelling study.

Luo Qingwei Q, Smith David P DP, David Michael M, Feletto Eleonora E et al.

Cancer prevalence is the number of people alive with a past cancer diagnosis in a specified number of previous years (e.g., last 5 or 30 years). This study estimates 1- to 30-year cancer prevalence in Australia for each year in 2025-2050, for 24 cancer types, the group of remaining cancers, and for all cancers combined. We used validated methods to estimate prevalence as a function of incidence and survival, using tabulated data from the Australian Institute of Health and Welfare and incorporating the effect of influential cancer-specific factors. The number of people living with cancer (cancers not yet cured) is estimated using the time-to-cure method. The 30-year prevalence is projected to increase by 57.1% from 1,666,020 (95% uncertainty interval [UI]: 1,553,825-1,784,900) in 2025 to 2,617,016 (95% UI: 2,333,949-2,947,174) in 2050. For people aged 80+ years, 30-year prevalence is projected to increase by 111.0% from 481,079 (95% UI: 448,799-515,286) in 2025 to 1,015,061 (95% UI: 917,670-1,125,036) in 2050. Breast cancer is projected to be the most prevalent cancer in Australia in 2050, followed by prostate, melanoma and colorectal cancer. For 30-year prevalence in 2050, 43.9% of people (1,149,364; 95% UI: 1,103,165-1,238,377) are estimated to be living with cancer (cancers not yet cured) and requiring initial treatment or ongoing care. A substantial increase in the number of people with a past cancer diagnosis in Australia is expected in 2025-2050. Expansion of appropriate services to meet the demand will be a key challenge for the health system in Australia. This work was not supported by a dedicated research grant. This work and open access publishing were supported by the Cancer Council NSW, through funding to the Daffodil Centre. KC is a recipient of a Fellowship from the National Health and Medical Research Council of Australia (APP1194679). JS is a recipient of a Cancer Institute NSW Career Development Fellowship (2022/CDF1154).

PMID 42694729
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about diphtheria+tetanus+pertussis combined vaccine